

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

## **1 NAME OF THE MEDICINAL PRODUCT**

Piasky 340 mg solution for injection/infusion

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 2 mL vial contains 340 mg of crovalimab.

Each mL of solution for injection/infusion contains 170 mg crovalimab.

Crovalimab is a humanised monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

## **3 PHARMACEUTICAL FORM**

Solution for injection/infusion (injection/infusion).

Clear to strongly opalescent and almost colourless to brownish-yellow solution. The solution has a pH of approximately 5.8 and an osmolality of approximately 297 mOsm/kg.

## **4 CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):

- In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
- In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.

### **4.2 Posology and method of administration**

Treatment should be initiated under the supervision of a physician experienced in the treatment of haematological disorders.

#### Posology

The recommended dosing regimen consists of one loading dose administered by intravenous infusion (on Day 1), followed by four additional weekly loading doses administered by subcutaneous injection (on Days 2, 8, 15, and 22). The maintenance dose starts on Day 29 and is then administered every 4 weeks by subcutaneous injection. The doses to be administered are based on the patient's body weight, as shown in Table 1.

For patients switching from treatment with another complement inhibitor, the first intravenous loading dose of Piasky should be administered at the time of the next scheduled complement inhibitor administration (see section 4.4 for additional information related to switching between complement

component 5 [C5] inhibitor treatments). The administration of the additional subcutaneous loading doses and maintenance doses of Piasky will follow as per the schedule shown in Table 1.

**Table 1: Piasky dosing regimen based on body weight**

<b>Body weight</b>	<b>≥ 40 kg to &lt; 100 kg</b>	<b>≥ 100 kg</b>
<b>Loading Dose</b>		
Day 1	1 000 mg (intravenous)	1 500 mg (intravenous)
Day 2, 8, 15, 22	340 mg (subcutaneous)	340 mg (subcutaneous)
<b>Maintenance dose</b>		
Day 29 and Q4W <sup>a</sup> thereafter	680 mg (subcutaneous)	1 020 mg (subcutaneous)

<sup>a</sup> Q4W=every 4 weeks

The dosing schedule is allowed to occasionally vary within 2 days of the scheduled administration day (except at Day 1 and Day 2). If this occurs, the subsequent dose should be administered according to the regular schedule.

#### *Duration of treatment*

Piasky is intended for long-term treatment unless the discontinuation of this medicinal product is clinically indicated (see section 4.4).

#### *Delayed or missed doses*

If an entire planned dose or part of a planned dose of Piasky is missed, the missing dose or remainder of the planned dose should be administered as soon as possible before the day of the next scheduled dose. The next dose should then be administered on the regular scheduled dosing day. Do not take two doses or administer more than the prescribed dose on the same day to make up for a missed dose.

#### *Dose modifications*

Modification of the maintenance dose is required if the patient's body weight changes by 10% or more to become consistently greater than or lower than 100 kg during the course of treatment (see Table 1 for recommended dose). Accordingly, the patient's body weight should be monitored periodically and on an ongoing basis, as appropriate.

#### Special populations

##### *Elderly*

No dose adjustment is required in patients ≥ 65 years of age, although experience with crovalimab in elderly patients in clinical studies is limited (see section 5.2).

##### *Renal impairment*

No dose adjustment is recommended for patients with mild, moderate or severe renal impairment (see section 5.2).

### *Hepatic impairment*

No dose adjustment is recommended for patients with mild hepatic impairment. Crovalimab has not been studied in patients with moderate to severe hepatic impairment and no recommendation on posology can be provided (see section 5.2).

### Paediatric population

No dose adjustment of crovalimab is required in paediatric patients 12 years of age or older with body weight  $\geq 40$  kg. The safety and efficacy of crovalimab in children less than 12 years of age and children with body weight  $< 40$  kg have not yet been established. No data are available.

### Method of administration

Piasky is administered as an intravenous infusion (first dose) and as a subcutaneous injection (subsequent doses).

#### *Intravenous administration*

Piasky should be prepared for intravenous administration using appropriate aseptic technique. Piasky must be diluted and administered by a healthcare professional as an intravenous infusion over 60 minutes  $\pm$  10 minutes (1 000 mg) or 90 minutes  $\pm$  10 minutes (1 500 mg). Piasky should not be administered as an intravenous push or bolus.

For instructions on dilution of the medicinal product before administration, see section 6.6.

The infusion of crovalimab may be slowed or interrupted if the patient develops an infusion related reaction. The infusion should be discontinued immediately if the patient experiences a serious hypersensitivity reaction (see section 4.4).

#### *Subcutaneous administration*

Piasky must be used undiluted and should be prepared using appropriate aseptic technique. It is recommended to inject Piasky into the abdomen. Within the abdomen, injection sites should be rotated with every injection. Injections should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.

#### *Administration by the patient and/or caregiver*

After proper training in subcutaneous injection technique, the patient may self-administer Piasky or the caregiver may administer Piasky without healthcare professional (HCP) supervision if the treating physician determines that it is appropriate.

Comprehensive instructions for the administration of Piasky are given at the end of the Package Leaflet.

## **4.3 Contraindications**

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Patients with unresolved *Neisseria meningitidis* infection.
- Patients who are not currently vaccinated against *Neisseria meningitidis* unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination (see section 4.4).

## 4.4 Special warnings and precautions for use

### Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

### Serious meningococcal infection

Due to its mechanism of action, the use of crovalimab may increase the patient's susceptibility to meningococcal infections (septicaemia and/or meningitis). Cases of serious or fatal meningococcal infections/sepsis have been reported in patients treated with terminal complement inhibitors, which is a known class effect.

Meningococcal infection may become rapidly life-threatening or fatal if not recognised and treated early. To reduce the risk of infection, all patients must be vaccinated with a tetravalent meningococcal vaccine at least 2 weeks prior to receiving the first dose of crovalimab. If immediate treatment with crovalimab is indicated in an unvaccinated patient, the required vaccine should be administered as soon as possible and patients should receive prophylactic antibiotics from the time they start crovalimab until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W, and B where available, are recommended to prevent infections with the commonly pathogenic meningococcal serogroups. Patients must maintain up to date vaccinations according to current local guidelines for vaccination use. If the patient is being switched from other terminal complement inhibitor treatment, physicians should verify that meningococcal vaccination is current according to local guidelines for vaccination use. Vaccination may activate the complement system further. As a result, patients with complement-mediated diseases, including PNH, may experience transient worsening of signs and symptoms of their underlying disease, such as haemolysis. Therefore, patients should be closely monitored for disease symptoms after the recommended vaccination.

Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to the prophylactic use of antibacterial agents based on local guidance. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps they need to take in seeking medical care immediately. Physicians must discuss the benefits and risks of treatment with Piasky with the patients and provide them with a patient/caregiver guide and a patient card.

### Other systemic infections

Due to its mechanism of action, crovalimab must be administered with caution to patients with active systemic infections. Patients may have increased susceptibility to infections, especially with *Neisseria* spp. and other encapsulated bacteria. Vaccinations for the prevention of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) infections should be administered according to local guidelines.

If local guidelines mandate vaccinations for the prevention of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) infections, this should be performed at least 2 weeks prior receiving the first dose of crovalimab. If immediate treatment with crovalimab is indicated in an unvaccinated patient, the required vaccine should be administered as soon as possible and patients should receive prophylactic antibiotics from the time they start crovalimab until 2 weeks after vaccination or according to local standard of care, whichever is longer.

If Piasky is administered to patients with active systemic infections, patients should be monitored closely for signs and symptoms of worsening infection. Patients were excluded from clinical studies with crovalimab if they had any active systemic bacterial, viral, or fungal infection within 14 days prior to starting treatment.

Patients should be provided with information from the package leaflet to increase their awareness of the signs and symptoms of potential serious infections.

### Type III immune complex reactions

Immune complex formation occurs in patients switching between complement inhibitors which bind different epitopes (see section 4.5). In some patients, the formation of these complexes can result in Type III immune complex mediated reactions, also referred to as Type III immune complex reactions. Patients who have never previously been treated with a C5 inhibitor or patients in whom previous C5 inhibitor treatment has been cleared from the body (i.e. at least 5.5 half-lives of the previous treatment have passed since the last dose) are not at risk of Type III immune complex reactions. Clinical studies with crovalimab reported adverse events of Type III immune complex mediated reactions (see section 4.8).

Signs and symptoms of Type III immune complex reactions observed in clinical studies were arthralgia and other musculoskeletal and connective tissue disorders, rash and other skin and subcutaneous disorders, pyrexia, asthenia/fatigue, gastrointestinal distress, headache and axonal neuropathy. Type III immune complex reactions may also manifest as renal abnormalities, however this was not observed during clinical studies with crovalimab.

Based on time-to-onset for Type III immune complex reactions observed in clinical studies, it is recommended that patients are monitored for the first 30 days after switching from eculizumab or ravulizumab to crovalimab (or vice-versa) for occurrence of the symptoms of Type III immune complex reactions. For mild or moderate Type III immune complex reactions, administration of symptomatic treatment (e.g. topical corticosteroids, antihistamines, antipyretics, and/or analgesics) may be considered. For severe reactions, oral or parenteral corticosteroid therapy can be initiated and tapered as clinically indicated.

### Infusion and injection-related reactions

Administration of crovalimab may cause infusion-related reactions or systemic injection-related reactions, depending on the route of administration. These may include allergic or hypersensitivity reactions (including anaphylaxis) but also a range of other symptoms such as headache or muscle pain.

In the event of a severe infusion-related reaction after intravenous Piasky administration, treatment should be interrupted and appropriate medical therapy should be administered. In the event of a severe injection-related reaction after subcutaneous administration or any incidence of serious allergic reaction following intravenous or subcutaneous administration, patients/caregivers should seek immediate medical attention and appropriate medical therapy should be administered. Patients should confirm with their healthcare professional whether treatment with Piasky can be continued.

### Serious haemolysis after treatment discontinuation in PNH patients

In case of Piasky discontinuation, patients who do not switch to another treatment for PNH must be closely monitored for signs and symptoms of serious intravascular haemolysis, identified by elevated lactate dehydrogenase (LDH) levels, along with sudden decrease in PNH clone size or haemoglobin, or re-appearance of symptoms such as fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. If signs and symptoms of haemolysis occur after discontinuation, including elevated LDH, consider restarting appropriate treatment.

### Immunogenicity leading to loss of exposure and efficacy

Patients may develop anti-drug antibodies (ADAs) that can interfere with crovalimab exposure. Development of ADAs may lead to loss of crovalimab exposure, which may subsequently result in loss of crovalimab efficacy. Loss of efficacy and loss of exposure resulting from ADA development has been observed in patients treated with crovalimab in clinical studies. Patients should be routinely

monitored for clinical signs of loss of exposure and efficacy, including serious intravascular haemolysis. In the event of persistent serious intravascular haemolysis despite compliant treatment with crovalimab, patients should be promptly assessed to evaluate the aetiology and the possibility of the development of ADAs leading to loss of exposure and efficacy should be considered. An assessment of the benefits vs risks of continuing crovalimab should be made and a switch to an alternative therapy should be considered. Patients/caregivers should be advised to seek immediate medical attention if the patient develops signs of worsening PNH. See sections 4.8 and 5.1.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Crovalimab and other C5 inhibitors bind different epitopes on C5 such that immune complexes comprised of the antibodies bridged by C5 may form when both are present in the circulation. These immune complexes, also referred to as drug-target-drug complexes (DTDCs), can comprise one or more units of C5 bound to both crovalimab and to another C5 inhibitor and are expected to be cleared within approximately 8 weeks (in the case of eculizumab). The immune complexes may be cleared after a longer duration in the case of switch from C5 inhibitors with an extended half-life such as ravulizumab. In some patients, the formation of these complexes results in Type III immune complex reactions (see sections 4.4 and 4.8). In patients switching from another C5 inhibitor therapy, a transient increase in clearance is observed due to the formation of the immune complexes, leading to a faster elimination of crovalimab. However, this transient increase in clearance is not clinically relevant and does not require dose adjustment in patients switching from another C5 inhibitor.

No dedicated interaction studies have been conducted.

Crovalimab is not expected to show pharmacokinetic interactions with other medicinal products interfering with the metabolising cytochrome P450 (CYP) enzymes, since the clearance pathways of immunoglobulins G (IgGs) are distinct from those of small molecules.

#### **4.6 Fertility, pregnancy and lactation**

##### Pregnancy

There is no data from the use of crovalimab in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). Human IgG is known to cross the placenta after first trimester of pregnancy. Based on its mechanism of action, crovalimab may potentially cause terminal complement inhibition in the foetal circulation.

Therefore, the use of Piasky may be considered in pregnant women if the clinical condition of the woman requires treatment with crovalimab.

##### Breast-feeding

It is not known whether crovalimab is excreted into human breast milk. Human IgG1 is known to be excreted in human milk. A risk to the breastfed infant cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue from Piasky therapy taking into account the benefit of breast-feeding for the infant and the benefit of therapy for the mother.

##### Fertility

No clinical data are available on the effect of crovalimab on human fertility. Animal data from repeated-dose toxicity studies showed no effect on male or female reproductive organs (see section 5.3).

## 4.7 Effects on ability to drive and use machines

Piasky has no or negligible influence on the ability to drive and use machines.

## 4.8 Undesirable effects

### Summary of the safety profile

The most common adverse reactions observed were Type III immune complex mediated reaction (18.9% in patients who switched from treatment with another C5 inhibitor to crovalimab), upper respiratory tract infection (18.6%), pyrexia (13.5%), headache (10.9%) and infusion- related reaction (10.2%). The most common serious adverse reactions observed were Type III immune complex mediated reaction (4.0% in patients who switched from treatment with another C5 inhibitor to crovalimab) and pneumonia (1.5%).

The safety results from the 44 patients in the COMPOSER study where the median treatment duration was 4.69 years (range: 0.4 - 6.3 years) did not reveal any additional safety concerns associated with long term use of crovalimab.

### Tabulated list of adverse reactions

The safety of crovalimab in patients with PNH was evaluated in three Phase III studies, COMMODORE 2 (BO42162), COMMODORE 3 (YO42311), and COMMODORE 1 (BO42161), and one Phase I/II study (COMPOSER, BP39144).

Table 2 lists the adverse reactions that have been reported in association with the use of crovalimab in a pooled analysis of 393 patients enrolled in the Phase III studies, unless otherwise stated. The median treatment duration for crovalimab based on the pooled analysis of 393 patients was 64 weeks (range: 0.1 - 136.4 weeks).

Adverse reactions are listed by MedDRA system organ class. The corresponding frequency category for each adverse reaction is based on the following convention: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1\ 000$  to  $< 1/100$ ), rare ( $\geq 1/10\ 000$  to  $< 1/1\ 000$ ), very rare ( $< 1/10\ 000$ ). Within each frequency category, adverse reactions are presented in the order of decreasing seriousness.



**Table 2: Summary of adverse reactions occurring in patients treated with Piasky**

MedDRA system organ class	Adverse reactions (MedDRA)	Frequency category
<b>Infections and infestations</b>	Upper respiratory tract infection	Very common
	Pneumonia	Common
	Respiratory Tract Infection	
	Urinary Tract Infection	
	Nasopharyngitis	
	Sepsis	Uncommon
	Septic shock	
	Bacteraemia	
	Pyelonephritis	
<b>Immune system disorders</b>	Type III immune complex mediated reaction*	Very common
	Hypersensitivity	Common
<b>Nervous system disorders</b>	Headache	Very common
<b>Gastrointestinal Disorders</b>	Abdominal pain	Common
	Diarrhoea	
<b>Skin and subcutaneous tissue disorders</b>	Rash	Common
<b>Musculoskeletal and connective tissue disorders</b>	Arthralgia	Common
<b>General disorders and administration site conditions</b>	Pyrexia	Very common
	Asthenia	Common
	Fatigue	
	Injection site reaction	Uncommon
<b>Injury, poisoning and procedural complications</b>	Infusion related reaction	Very common
	Injection-related reaction	Common

\*Type III immune complex mediated reaction (also referred to as Type III immune complex reaction) is limited to patients who switch from another C5 inhibitor to crovalimab or from crovalimab to

another C5 inhibitor. The frequency of Type III immune complex reactions is reported for a subset of N=201 patients who switched from treatment with another C5 inhibitor to crovalimab, with incidence rates being calculated using these N=201 patients as the denominator. See below.

### Description of selected adverse reactions

#### *Type III immune complex reactions (see sections 4.4 and 4.5)*

Across Phase III studies, 19.4% (39 out of 201) of patients who switched from treatment with eculizumab or ravulizumab to crovalimab experienced a Type III immune complex reaction (reported as Type III immune complex mediated reaction). Of these 39 patients, 2 patients experienced a second Type III immune complex reaction after discontinuing crovalimab and switching to ravulizumab. The most common signs and symptoms that were reported were arthralgia and rash, and other symptoms reported include pyrexia, headache, myalgia, abdominal pain, asthenia/fatigue and axonal neuropathy. The median time to onset of a Type III immune complex reaction in patients who switched from treatment with eculizumab or ravulizumab to crovalimab was 1.6 weeks (range: 0.7 - 4.4 weeks), with 5.1% of patients (2 of 39) experiencing a Type III immune complex reaction with a time to onset that exceeded 4 weeks. Most cases of Type III immune complex reaction were transient with a median duration of 1.7 weeks (range 0.4 – 34.1 weeks). The majority of patients experienced a Grade 1 or 2 event (23 of 39 patients), with Grade 3 events affecting 8% (16 of 39) of crovalimab-treated patients who switched from eculizumab or ravulizumab. Most events resolved with no change in study treatment with crovalimab.

In the COMPOSER study, among 26 patients who switched from eculizumab to crovalimab, 2 patients each reported 1 adverse event of Type III immune complex reaction. These events were mild/moderate and non-serious. One additional patient developed a mild Type III immune complex reaction after discontinuing crovalimab and switching to a different C5 inhibitor.

#### *Immunogenicity*

Across two randomised Phase III studies (COMMODORE 1 and COMMODORE 2) and one single-arm Phase III study (COMMODORE 3), ADA status was evaluable in 392 patients. Out of these 392 patients, 118 (30.1%) were ADA-positive. No differences in the rates of adverse reactions typically associated with immunogenicity (such as infusion-related reactions, injection site reactions, or hypersensitivity) were observed between ADA-positive and ADA-negative patients (see section 5.1).

#### *Immunogenicity leading to loss of exposure and efficacy*

Patients may develop ADAs that can interfere with crovalimab exposure. Out of 392 patients evaluated for ADA status, partial or complete loss of exposure associated with ADA onset was observed in 23 patients (5.9%); among them, 17 (4.3%) had a loss of pharmacological activity coinciding with a loss of exposure and with loss of efficacy, manifesting as a sustained loss of haemolysis control in 7 patients (1.8%).

In case of clinical signs of loss of efficacy, prompt evaluation by a healthcare professional should be sought (see section 4.4).

#### *Infusion and Injection-Related Reactions*

Across Phase III studies, 10.2% of patients who were treated with crovalimab experienced an infusion related reaction. The most common signs and symptoms that were reported were headache (7.1%), rash (0.8%), dizziness (0.8%), abdominal pain (0.5%), erythema (0.5%), nausea (0.5%), pyrexia (0.5%), and paraesthesia (0.3%). All events reported were Grade 1-2.

Across Phase III studies, 8.4% of patients who were treated with crovalimab experienced an injection-related reaction. The most common signs and symptoms that were reported were headache

(2.5%), injection site erythema (1.0%), injection site pain (1.0%), and injection site rash (1.0%). The majority of events were Grade 1-2.

#### *Infections with encapsulated bacteria*

Based on its mechanism of action, the use of crovalimab may potentially increase the risk of infections, particularly infections caused by encapsulated bacteria including *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* (see section 4.4).

Across Phase III studies, infections with encapsulated bacteria that were reported were *Klebsiella pneumoniae*, *Klebsiella* (not otherwise specified), *Haemophilus influenzae* and *Neisseria subflava*, the latter of which caused an adverse event of bacteraemia in a patient.

#### Paediatric population

In 12 paediatric PNH patients with body weight  $\geq 40$  kg (aged 13-17 years old) included in COMMODORE 1, COMMODORE 2 and COMMODORE 3 studies, the safety profile appeared similar to that observed in adult PNH patients. The adverse reactions associated with crovalimab that were reported in paediatric PNH patients are upper respiratory tract infection (16.7%), urinary tract infection (16.7%), fatigue (16.7%), pyrexia (16.7%), headache (8.3%), infusion-related reaction (8.3%) and injection-related reaction (8.3%).

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

### **4.9 Overdose**

In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Immunosuppressants, Complement inhibitors, ATC code: L04AJ07

#### Mechanism of action

Crovalimab is a recombinant humanised immunoglobulin G1 (IgG1)-based monoclonal antibody that specifically binds with high affinity to component 5 (C5) of the complement system, inhibiting its cleavage into C5a and C5b and thus preventing the formation of the membrane attack complex (MAC). Crovalimab causes terminal complement activity inhibition. In patients with PNH, crovalimab inhibits terminal complement-mediated intravascular haemolysis.

#### Pharmacodynamic effects

In clinical studies with PNH patients, a concentration-dependent inhibition of terminal complement activity following treatment with crovalimab was observed. Terminal complement activity (CH50 as measured by Liposome Immunoassay [LIA]) inhibition was achieved immediately by the end of the initial crovalimab infusion and was generally sustained through the duration of crovalimab treatment.

Similarly, mean free C5 concentrations decreased to low levels ( $< 0.0001$  g/L) in comparison to baseline and remained low throughout the treatment period.

Free C5 and CH50 levels were similar between paediatric and adult patients treated with crovalimab.

### Clinical efficacy and safety

The safety and efficacy of crovalimab in patients with PNH were evaluated in a non-inferiority Phase III study (COMMODORE 2, BO42162) and supported by clinical evidence from two additional Phase III studies (COMMODORE 3, YO42311 and COMMODORE 1, BO42161).

In all Phase III studies, patients were required to be vaccinated against *Neisseria meningitidis*, either within 3 years prior to the start of treatment or within 7 days after starting treatment with crovalimab. Patients vaccinated within 2 weeks prior to initiating crovalimab or after the start of study treatment received appropriate prophylactic antibiotics from the time they started study until at least 2 weeks after the vaccination (see section 4.4 for warnings and precautions related to serious meningococcal infection). Patients with a history of *Neisseria meningitidis* infection in the 6 months prior to screening and up to the first study drug administration were excluded.

Patients were also excluded if they had a history of allogenic bone marrow transplantation.

Crovalimab was administered in Phase III studies in accordance with the recommended dose described in section 4.2. Rescue doses of 340 mg of crovalimab administered intravenously were allowed based on the investigators' judgement if a patient experienced signs and symptoms of PNH; however, these studies were not designed to evaluate the impact of rescue dosing on the efficacy of crovalimab. Eculizumab was administered per local prescribing information, or in a country without access to commercial eculizumab (COMMODORE 2), then eculizumab 600 mg was given intravenously once weekly for the first 4 weeks, followed by 900 mg every 2 weeks thereafter. Rescue doses of eculizumab were not allowed on study.

The Phase III studies consisted of a primary treatment period of 24 weeks, after which patients had the option to continue/switch to crovalimab in an extension period.

### *Study in complement inhibitor-naïve patients with PNH*

#### COMMODORE 2 (Study BO42162)

COMMODORE 2 was a Phase III, randomised, open-label, active-controlled, multicentre clinical study designed to evaluate the efficacy and safety of crovalimab compared to eculizumab in patients with PNH who were not previously treated with a complement inhibitor. 204 patients (body weight  $\geq 40$  kg), were randomised 2:1 to receive either crovalimab ( $n = 135$ ) or eculizumab ( $n = 69$ ). The study additionally enrolled 6 paediatric patients (aged  $< 18$  years and with body weight  $\geq 40$  kg) in a descriptive arm to receive crovalimab (see section 5.1). Eligible patients had high disease activity at screening, demonstrated by LDH level  $\geq 2 \times$  upper limit of normal (ULN) and by the presence of one or more PNH-related signs or symptoms in the past 3 months: fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea) anaemia (haemoglobin  $< 10$  g/dL), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cell (pRBC) transfusion due to PNH.

Randomisation was stratified by the most recent LDH value ( $\geq 2$  to  $\leq 4 \times$  ULN, or  $> 4 \times$  ULN) and by the transfusion history (0,  $> 0$  to  $\leq 6$ , or  $> 6$  pRBC units administered within 6 months prior to randomisation); the respective stratification categories were balanced across treatment arms.

Demographics and baseline characteristics of the randomised study population were generally balanced between the treatment arms and are presented in Table 3.

**Table 3: Demographics and baseline characteristics for COMMODORE 2 (randomised population)**

Parameters	Crovalimab (N= 135)	Eculizumab (N= 69)
Age (years) at PNH diagnosis		
Mean (SD)	35.8 (15.5)	37.4 (16.4)
Median (Range)	31.0 (11.5 – 74.7)	32.1 (11.2 - 76.8)
Age (years) at first administration of the study treatment*		
Mean (SD)	40.5 (15.2)	41.9 (16.0)
Median (Range)	36.0 (18 – 76)	38.0 (17 – 78)
< 18 years (n, %)	0	2 (2.9%)
18 – 64 years (n, %)	122 (90.4%)	58 (84.1%)
≥ 65 years (n, %)	13 (9.6%)	9 (13.0%)
Weight		
40 – < 100 kg (n, %)	131 (97.0%)	66 (95.7%)
≥ 100 kg (n, %)	4 (3.0%)	3 (4.3%)
Sex		
Male (n, %)	77 (57.0%)	35 (50.7%)
Female (n, %)	58 (43.0%)	34 (49.3%)
LDH levels at baseline (x ULN)		
Median (Range)	7.0 (2.0 -16.3)	7.7 (2.0 - 20.3)
History of pRBC transfusions in the 12 months prior to screening		
Yes (n, %)	103 (77.4%)	50 (73.5%)
pRBC units transfused in the 12 months prior to screening		
Median (Range)	3.8 (0 - 43.5)	3.0 (0 - 41.0)
Total PNH granulocyte clone size (%)		
Median (Range)	91.4 (5.8 - 100)	93.6 (6.8 - 99.9)
Total PNH monocyte clone size (%)		
Median (Range)	90.9 (42.5 - 99.9)	95.1 (41.5 - 99.9)
Total PNH erythrocytes clone size (%)		
Median (Range)	25.3 (3.5 - 96.0)	44.6 (0.1 – 88.9)
Haemoglobin levels at baseline (g/L)		
Median (IQR)	85.0 (77.0 - 93.0)	87.0 (81.0 - 97.0)
History of aplastic anaemia		
Yes (n, %)	53 (39.3%)	26 (37.7%)
History of myelodysplastic syndrome		
Yes (n, %)	6 (4.4%)	6 (8.7%)
History of Major Adverse Vascular Event (MAVE)		
Yes (n, %)	21 (15.6%)	10 (14.5%)
Medicinal products at baseline**		
Anticoagulants (n, %)	35 (25.9%)	17 (24.6%)
Steroids (n, %)	46 (34.1%)	25 (36.2%)
Immunosuppressive therapy (n, %)	23 (17.0%)	13 (18.8%)
PNH-related signs or symptoms within 3 months prior to screening		
Abdominal Pain	21 (15.6%)	11 (15.9%)
Anaemia	109 (80.7%)	57 (82.6%)
Dysphagia	8 (5.9%)	2 (2.9%)
Erectile Dysfunction	13 (9.6%)	4 (5.8%)
Fatigue	113 (83.7%)	63 (91.3%)

Parameters	Crovalimab (N= 135)	Eculizumab (N= 69)
Haemoglobinuria	79 (58.5%)	45 (65.2%)
MAVE (including Thrombosis)	9 (6.7%)	5 (7.2%)
Shortness of Breath (Dyspnoea)	29 (21.5%)	14 (20.3%)

Note: IQR = interquartile range.


\* Two adolescent patients (both 17 years of age) were randomised into the eculizumab arm prior to the opening of the separate descriptive paediatric arm. Both patients switched to crovalimab in the extension period after completing the primary treatment period; one patient was still < 18 years, while the other patient had turned 18 years at the time of first crovalimab treatment. See below “Paediatric population”

\*\*Includes medicinal products that were started prior to initiation of study treatment, and were either stopped before or were ongoing at time of initiation of study treatment.

The primary objective of the study was to evaluate the efficacy of crovalimab compared with eculizumab, based on the non-inferiority (NI) assessment of the following co-primary endpoints: haemolysis control, measured by the mean proportion of patients with  $LDH \leq 1.5 \times ULN$  from Week 5 to Week 25; and the proportion of patients who achieved transfusion avoidance, defined as patients who are pRBC transfusion-free, from baseline through Week 25. Secondary efficacy endpoints included the proportion of patients with breakthrough haemolysis, proportion of patients with stabilised haemoglobin, and change in fatigue (measured by the FACIT [Functional Assessment of Chronic Illness Therapy]-Fatigue scale) from baseline to Week 25.

Crovalimab was non-inferior compared to eculizumab for both co-primary endpoints of haemolysis control and transfusion avoidance and for the secondary endpoints of haemoglobin stabilisation and breakthrough haemolysis (Figure 1). Figure 2 shows the proportion of patients with  $LDH \leq 1.5 \times ULN$  from baseline through Week 25.

**Figure 1: Co-primary and secondary endpoint results in (COMMODORE 2, primary analysis population)**




Note: The triangles indicate the non-inferiority margins, and the circles indicate point estimates. CI = confidence interval;

<sup>1</sup> One patient randomised to crovalimab did not have post-baseline LDH and was not included in the primary efficacy analysis.

<sup>2</sup> For Transfusion Avoidance and Haemoglobin Stabilisation, difference is calculated as a weighted difference of crovalimab minus eculizumab. For Breakthrough Haemolysis, difference is calculated as a weighted difference of eculizumab minus crovalimab.

<sup>3</sup> Odds ratio calculated as odds for crovalimab divided by odds for eculizumab

**Figure 2: Proportion of patients with LDH  $\leq 1.5 \times$  ULN from baseline through Week 25, with 95% CIs (COMMODORE 2, primary analysis population)**



*Studies in PNH patients previously treated with complement C5 inhibitor therapy*

#### COMMODORE 1 (Study BO42161) - randomised eculizumab switch patients

COMMODORE 1 was a Phase III, randomised, open-label, active-controlled, multicentre clinical study evaluating the safety, pharmacodynamics, pharmacokinetics and exploratory efficacy of crovalimab in patients switching from another complement C5 inhibitor therapy. The primary objective of this study was to evaluate safety (see section 4.8). Eighty-nine patients were randomised 1:1 to receive either crovalimab (n = 45) or eculizumab (n = 44). Patients were eligible to enroll into the randomised arms if they were switching from approved doses of eculizumab and had haemolysis control at screening, defined by LDH level  $\leq 1.5 \times$  ULN. Patients were excluded if they had a Major Adverse Vascular Event (MAVE) within the 6 months prior to first study drug administration. Randomisation was stratified by patient transfusion history (whether a patient received a transfusion of pRBCs within 12 months prior to randomisation).

Demographics and baseline characteristics of the randomised study population were balanced between the treatment arms. The median LDH value at baseline was  $1.01 \times$  ULN (range: 0.6-1.7) for crovalimab and  $0.96 \times$  ULN (range: 0.7-1.9) for eculizumab. The proportion of patients with a history of transfusions in the 12 months prior to screening was 22.7% in the crovalimab arm and 25% in the eculizumab arm, with a mean (SD) of 1.6 (3.7) and 2.3 (5.4) units of transfused pRBC in the crovalimab and eculizumab arms respectively. The baseline median (range) PNH clone sizes for total erythrocytes, monocytes, and granulocytes for crovalimab arm vs eculizumab arms are as follows: 44.6% (2.6 - 100) vs 54.2% (1.3 - 100), 88.6% (13.8 - 100) vs 96.4% (7.6 - 99.9), and 88.1% (5.2 - 100), vs 95.7% (7.9 - 99.9), respectively.

Out of 89 randomised patients, efficacy was evaluated in an exploratory fashion in 76 (n=39 for crovalimab and n=37 for eculizumab) that were enrolled at least 24 weeks before the cut-off date for the primary analysis. Overall, the results of the exploratory efficacy endpoints showed that patients switching to crovalimab from eculizumab maintained disease control. The mean proportion of patients maintaining haemolysis control from baseline through Week 25 was 92.9% [95% CI: 86.6, 96.4] for patients randomised to crovalimab and 93.7% [95% CI: 87.3, 97.0] for patients randomised to

eculizumab. Transfusion avoidance was observed in 79.5% [95% CI: 63.1, 90.1] of patients randomised to crovalimab and 78.4% [95% CI: 61.3, 89.6] of patients randomised to eculizumab.

#### COMMODORE 1 (Study BO42161) and COMMODORE 2 (Study BO42162) - clinically stable switch patients

Supportive data in clinically stable eculizumab switch patients was reported from patients in COMMODORE 1 (25 efficacy evaluable patients) and COMMODORE 2 (29 efficacy evaluable patients) that had been treated with eculizumab for at least 24 weeks in the primary treatment period and had LDH  $\leq 1.5 \times$  ULN at switch-to-crovalimab baseline.

Efficacy was evaluated in the patients that had at least 24 weeks of exposure to crovalimab (or otherwise discontinued prior to having reached 24 weeks of treatment). The mean proportion of clinically stable switch patients maintaining haemolysis control from switch baseline through switch Week 25 in COMMODORE 1 and COMMODORE 2 was 98.7% [95% CI: 96.2, 99.5] and 95.3% [95% CI: 89.5, 97.9], respectively. Transfusion avoidance was observed in 80.0% [95% CI: 58.70, 92.39] and 86.2% [95% CI: 67.43, 95.49] of the clinically stable switch patients, respectively. These results in clinically stable eculizumab switch patients were consistent with the results in randomised eculizumab switch patients during the primary treatment period of COMMODORE 1.

Furthermore, in the non-randomised arm of COMMODORE 1, of the 19 clinically stable patients switching from ravulizumab, 95.8% [95% CI: 89.11, 98.43] maintained haemolysis control and 57.9% [95% CI: 33.97, 78.88] patients were transfusion avoidant from baseline to Week 25.

#### Immunogenicity

As with all therapeutic proteins, there is the potential for immune response to crovalimab.

Immunogenicity assay results are highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medicinal products and underlying disease. For these reasons, comparison of incidence of antibodies to crovalimab with the incidence of antibodies to other products may be misleading.

In the Phase III study COMMODORE 2, treatment-emergent anti-drug antibodies (ADAs) were observed in 35.0% (49/140) of treatment-naïve patients who received crovalimab and 38.2% (26/68) of patients who switched from treatment with another C5 inhibitor to crovalimab. The median time to the development of first post-baseline ADAs was 16.1 weeks (range: 1.1 to 72.3 weeks), and 16.6 weeks (range: 2.1 to 36.3 weeks) in the treatment-naïve patients and patients who were previously treated with another C5 inhibitor, respectively. Across Phase III studies, the incidence of treatment-emergent ADAs was 35.1% (67 patients out of 191) and 25.4% (51 patients out of 201) in treatment-naïve and patients who switched from treatment with another C5 inhibitor to crovalimab, respectively.

Across Phase III studies, median concentration time-courses in ADA-positive patients were slightly lower in comparison to ADA-negative patients. Despite this effect, concentrations remained above 100 µg/mL (threshold for complete terminal complement inhibition) in more than 80% of ADA-positive patients. ADA presence was not associated with clinically meaningful impact on pharmacokinetics, pharmacodynamics, and efficacy in most of the patients. However, out of 392 patients evaluated for ADA status, partial or complete loss of exposure associated with ADA onset was observed in 23 patients (5.9%); among them, 17 (4.3%) ADA positive patients had a loss of pharmacological activity (based on CH50 or free C5) coinciding with a loss of exposure, and loss of efficacy manifested as a sustained loss of haemolysis control in 7 patients (1.8%). There was no evidence for a clinical impact of ADA status on the safety profile of Piasmy (see sections 4.4 and 4.8).



### Paediatric population

Ten paediatric patients (with body weight  $\geq 40$  kg) treated with crovalimab in COMMODORE 2 (n = 7; 13 – 17 years old) and COMMODORE 3 (n = 3; 15 – 17 years old) were evaluable for efficacy.

Nine patients were treatment-naïve and 1 patient switched from eculizumab to crovalimab in the extension period. All paediatric patients received the same dosing as adult patients based on body weight. All 9 treatment-naïve patients achieved haemolysis control (defined as LDH  $\leq 1.5 \times$  ULN) by Week 4 and this was maintained in 7 patients at each visit from baseline to Week 25; the patient switching from eculizumab to crovalimab maintained haemolysis control through 24 weeks of treatment in the extension period. Seven out of the 10 paediatric patients achieved transfusion avoidance and haemoglobin stabilisation, and no patients had a breakthrough haemolysis event during the 24-week treatment period.

Overall, the treatment effect of crovalimab in paediatric PNH patients was similar to that observed in adult PNH patients.

The European Medicines Agency has deferred the obligation to submit the results of studies with Piasky in one or more subsets of the paediatric population with PNH (see section 4.2 for information on paediatric use).

## **5.2 Pharmacokinetic properties**

The pharmacokinetics of crovalimab have been characterised both in healthy volunteers and in patients with PNH. The pharmacokinetics were characterised using non-linear mixed effects pharmacokinetic analysis methods, based on a pooled database composed of 9 healthy volunteers and 210 and 211 treatment-naïve patients and patients who switched from previous treatment with another C5 inhibitor to crovalimab, respectively.

The concentration-time course of crovalimab is best described using a two-compartment open model with first-order elimination and a first order subcutaneous absorption constant. To describe the transient increase in clearance due to the formation of immune complexes observed in patients who switched from treatment with another C5 inhibitor to crovalimab, an additional time-varying clearance parameter, which decreases exponentially with time, was added. At steady state, exposure is expected to be similar between treatment naïve and switch patients.

### Absorption

The absorption rate constant was estimated to be  $0.126 \text{ day}^{-1}$  [CV%: 38.3]. Following subcutaneous administration, the bioavailability was estimated at 83.0% [CV%: 116].

### Distribution

The central volume of distribution was estimated to be 3.23 L [CV%: 22.4] and the peripheral volume of distribution was estimated as 2.32 L [CV%: 70.6].

The small volume of distribution indicates that crovalimab is likely to be distributed mainly in serum and/or in vascular rich tissues.

### Biotransformation

The metabolism of crovalimab has not been directly studied. IgG antibodies are mainly catabolised by lysosomal proteolysis and then eliminated from or reused by the body.

### Elimination

The clearance was estimated to be 0.0791 L/day [CV%: 20.6]. The terminal half-life of crovalimab was estimated as 53.1 days [CV%: 39.9], which is longer compared to other humanised IgG antibodies. This long half-life is consistent with the recycling properties of crovalimab.

### Special populations

No pharmacokinetic studies with crovalimab have been conducted in special populations. Bodyweight was shown to be a significant covariate, with clearances and volumes of distribution increasing and crovalimab exposure decreasing as bodyweight increases. Therefore, posology of crovalimab is based on the bodyweight of the patient (see section 4.2).

After inclusion of bodyweight in the model, the population pharmacokinetics analyses in patients with PNH showed that age (13 – 85 years) and gender did not meaningfully influence the pharmacokinetics of crovalimab. No further dose adjustment is required.

Race/ethnicity was also shown not to have an impact on the pharmacokinetics of crovalimab; however, data are limited in Black patients and therefore not considered conclusive in this population.

### *Elderly*

No dedicated studies have been conducted to investigate the pharmacokinetics of crovalimab in patients aged  $\geq 65$  years, however 46 (10.9%) elderly PNH patients were enrolled in clinical studies, including 35 patients aged 65-74 years, 10 patients aged 75-84 years, and 1 patient aged  $\geq 85$  years. The data obtained in PNH clinical studies indicates that exposure in patients aged  $\geq 65$  years is comparable to that of younger patients in other age groups, however, due to the limited data in patients  $\geq 85$  years, the pharmacokinetics of crovalimab in those subjects is unknown.

### *Renal impairment*

No dedicated studies have been conducted to investigate the pharmacokinetics of crovalimab in patients with renal impairment, however the data obtained in PNH clinical studies (62 [14.7%] patients with mild renal impairment, 38 [9%] patients with moderate renal impairment, and 4 [1%] patients with severe renal impairment) indicate that exposure in patients with mild, moderate, or severe renal impairment is comparable to that of patients without renal impairment. However, limited data were obtained for patients with severe renal impairment in PNH clinical studies.

### *Hepatic impairment*

No dedicated studies have been conducted in patients with hepatic impairment, however data obtained in PNH clinical studies indicate that exposure in patients with mild hepatic impairment (46 [11%] as graded based on alanine aminotransferase levels) are comparable to that of patients without hepatic impairment. Limited pharmacokinetic data were available in PNH patients with moderate (0 [0%]) to severe (1[0.23%]) hepatic impairment, therefore the impact of moderate or severe hepatic impairment on the pharmacokinetics of crovalimab is unknown and no dose recommendation can be provided (see section 4.2).

### Paediatric population

Data obtained in 12 paediatric patients (13-17 years old) in the PNH clinical studies indicates that exposure in paediatric patients 12 years of age or older with a weight of 40 kg and above was found to be comparable to that of adult patients.

### **5.3 Preclinical safety data**

Non-clinical data revealed no special hazard related to crovalimab treatment for humans based on conventional studies of, repeated dose toxicity (including safety pharmacology endpoints), and toxicity to reproduction and development.

#### Genotoxicity

No dedicated studies have been performed to establish the genotoxic potential of crovalimab. Monoclonal antibodies are not expected to interact directly with DNA or other chromosomal material.

#### Carcinogenicity

No studies have been performed to establish the carcinogenic potential of crovalimab. Assessment of available evidence related to pharmacodynamic effects and animal toxicology data do not indicate carcinogenic potential of crovalimab.

#### Reproductive and developmental toxicity

Repeated administration of crovalimab to pregnant cynomolgus monkeys during the gestation period induced no maternal toxicity and did not affect pregnancy outcome. No effects on the viability, growth and development of the infants were observed during the 6-month postnatal period.

#### Fertility

No effects on female or male reproductive organs were observed in cynomolgus monkeys following repeated administration of crovalimab for up to 6 months. Separate animal fertility studies have not been conducted with crovalimab.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Histidine  
Aspartic acid  
Arginine hydrochloride  
Poloxamer 188  
Water for injections

### **6.2 Incompatibilities**

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

### **6.3 Shelf life**

#### Unopened vial

3 years.

Prior to administration, unopened vials of Piasky may be stored out of the refrigerator at room temperature if needed and then returned to refrigeration. For temperature excursions outside 2 °C – 8 °C, the unopened vial can be kept at room temperature (up to 30 °C) in its outer carton for a cumulative period of no longer than 7 days. Discard if stored out of the refrigerator at room temperature for longer than 7 days.

#### Diluted solution for intravenous infusion

From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the diluted solution for intravenous infusion should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

If the diluted solution is prepared under controlled and validated aseptic conditions, the medicinal product can be stored in the refrigerator at 2 °C to 8 °C and at room temperature (up to 30 °C). Detailed storage conditions of the prepared solution for infusion depending on the type of infusion bags used are provided in Table 4.

**Table 4: Storage conditions for the solution for infusion prepared using aseptic conditions**

Infusion bags	Storage conditions
PO/PE/PP	Up to 30 days at 2 °C to 8 °C protected from light, and up to 24 hours at room temperature (up to 30 °C) under ambient light conditions. Protect from direct sunlight.
PVC	Up to 12 hours at 2 °C to 8 °C protected from light, and up to 12 hours at room temperature (up to 30 °C) under ambient light conditions. Protect from direct sunlight.

polyolefins (PO), polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC)

#### Undiluted solution for subcutaneous injection

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C, unless preparation has taken place in controlled and validated aseptic conditions.

If Piasky is transferred from the vial to the syringe under controlled and validated aseptic conditions, the medicinal product in the capped syringe can be stored in the refrigerator at 2 °C to 8 °C for up to 14 days protected from light and at room temperature (up to 30 °C) for up to 24 hours at ambient light.

Piasky solution must be protected from direct sunlight.

### **6.4 Special precautions for storage**

#### Unopened vial

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

For storage conditions of the diluted solution for intravenous infusion and the undiluted solution for subcutaneous injection, see section 6.3.

### **6.5 Nature and contents of container**

Solution for injection/infusion in a 2 mL single-use vial (Type I glass) with a stopper (rubber) and a seal (aluminium).

Each carton contains one vial.

## 6.6 Special precautions for disposal and other handling

Piasky vial is for single use only.

Piasky is used diluted for intravenous infusion or undiluted for subcutaneous injection.

Piasky should be inspected visually to ensure there is no particulate matter or discolouration prior to administration. Piasky is clear to strongly opalescent, and almost colourless to brownish-yellow solution. Piasky should be discarded if the medicinal product looks cloudy, discoloured or has particles in it.

### Intravenous administration

Piasky must be prepared by a healthcare professional under aseptic technique. Piasky solution must be diluted in sodium chloride 9 mg/mL (0.9%) solution for infusion prior to administration. A 0.2 µm in-line filter must be used with the infusion set during administration.

A dedicated infusion line must be used during intravenous administration.

### *Dilution*

1. Withdraw the required volume of Piasky from the vial (see Table 5) using a sterile syringe and dilute into the infusion bag. Multiple vials need to be used to meet the required volume of Piasky to be added to the infusion bag. Discard any unused portion left in the vial.

Dilution of Piasky in infusion bags containing sodium chloride 9 mg/mL (0.9%) solution for infusion must be in the range of 4-15 mg/mL (final concentration after dilution).

Intravenous infusion bags of a volume of 100 mL or 250 mL can be used.

**Table 5: Dose example volume determination**

Dose (mg)	Concentration in bag (mg/mL)	Volume of Piasky in 0.9% sodium chloride solution * (mL)	Size of infusion bags (mL)
1 000	4	5.9	250
1 500	6	8.8	250
1 000	10	5.9	100
1 500	15	8.8	100

\* Each 340 mg vial contains a nominal fill volume of 2.0 mL

2. Gently mix the infusion bag by slowly inverting the bag. Do not shake.
3. Inspect the infusion bag for particles and discard if present.
4. Flushing of infusion line is required in order to ensure complete administration of the entire dose.

No incompatibilities have been observed between Piasky and intravenous infusion bags with product-contacting materials made of polyvinyl chloride (PVC), or polyolefins (PO) such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product-contacting materials made of PVC, PE, polyurethane (PU), polybutadiene (PBD), acrylonitrile butadiene styrene (ABS), polycarbonate (PC), or polytetrafluorethylene (PTFE).

For storage conditions of the infusion bags, see section 6.3.

### Subcutaneous administration

Piasky should be used undiluted and should be prepared using aseptic technique. A syringe, a transfer needle and an injection needle are needed to withdraw Piasky solution from the vial and inject it subcutaneously.

Each injection is of a volume of 2 mL, corresponding to 340 mg. A 2 mL-size or 3 mL-size syringe should be used for each injection. A dose of 680 mg is achieved by performing two consecutive subcutaneous injections of 340 mg. A dose of 1 020 mg is achieved by performing three consecutive subcutaneous injections of 340 mg.

#### *2 mL or 3 mL syringe*

Criteria: Transparent polypropylene or polycarbonate syringe with Luer-Lock tip (in case not locally available, a syringe with Luer Slip tip can be used), sterile, single-use, latex-free and non-pyrogenic.

#### *Transfer needle*

Criteria: Stainless steel, sterile, preferably gauge 18 G with single bevel at approximately 45 degrees to reduce risk of needle stick injury, or gauge 21 G standard needle as an alternative, single use, latex free and non-pyrogenic. A transfer needle without filter is recommended.

#### *Injection needle*

Criteria: Hypodermic needle, stainless steel, sterile, gauge 25 G, 26 G or 27 G, length from 9 to 13 mm, single use, latex free and non-pyrogenic, preferably including safety needle shield.

Please see section 4.2 for additional information on administration.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused or shared with others.
- Place all used needles and syringes into a sharp container (puncture-proof disposable container).

## **7      MARKETING AUTHORISATION HOLDER**

Roche Registration GmbH  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

## **8      MARKETING AUTHORISATION NUMBER(S)**

EU/1/24/1848/001

## **9      DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 22 August 2024

## **10     DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>

## **ANNEX II**

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE  
SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE  
FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY  
AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE  
MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO  
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL  
PRODUCT**



**A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer(s) of the biological active substance

Roche Diagnostics GmbH  
Nonnenwald 2  
82377 Penzberg  
Germany

Name and address of the manufacturer(s) responsible for batch release

Roche Pharma AG  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

**Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

**Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## **Additional risk minimisation measures**

Prior to the launch of Piasky in each Member State, the Marketing Authorisation Holder (MAH) must agree with the National Competent Authority about the content and format of the educational materials, vaccination/re-vaccination reminder, and controlled access program, including communication media, distribution modalities, and any other aspects of the program.

The educational materials and controlled access program is aimed at informing healthcare professionals (HCPs) on the risks of Piasky and how to minimise and manage safety concerns through appropriate vaccination, and at patients/caregivers to inform them about the signs and symptoms of the risks, the best course of action when these risks present themselves, and when to seek urgent attention from their healthcare provider.

The MAH shall ensure that in each Member State where Piasky is marketed, all healthcare professionals and patients/caregivers who are expected to prescribe/dispense and use Piasky have access to/are provided with the following educational package:

- Guide for healthcare professionals
- Patient/caregiver guide
- Patient card
- Vaccination/re-vaccination reminders aimed at healthcare professionals

The guide for healthcare professionals (HCPs) will contain information about serious infections, meningococcal infection, and serious haemolysis after crovalimab discontinuation in PNH patients, and may include:

- Details on how to minimise the safety concern through appropriate vaccination, monitoring and management
- Key messages to convey in patient counselling
- Instructions on how to handle possible adverse events
- Remarks on the importance of reporting on adverse reactions

The MAH shall ensure that in each Member State where Piasky is marketed, a controlled access program of Piasky is in place. This additional risk minimisation measure aims to manage the important risk of meningococcal infection and to specifically ensure that the patient receives the appropriate vaccination against *Neisseria meningitidis* infection and prophylactic antibiotics as required in the product information. The targeted audience for this additional risk minimisation measure is the HCP/pharmacist who prescribes/dispenses crovalimab to the patients.

The MAH shall send annually to prescribers or and pharmacists who prescribe/dispense crovalimab, a reminder to ensure that patients receiving crovalimab have been vaccinated (using the tetravalent vaccine) against *Neisseria meningitidis* infections.

The patient/caregiver guide will contain information about serious infections, infusion- and injection-related reactions, meningococcal infection, and serious haemolysis after crovalimab discontinuation in PNH patients, and may include:

- A description of the signs and symptoms of the risks
- A description of the best course of action if signs and symptoms of those risks present themselves
- A description of when to seek urgent attention from the health care provider should signs and symptoms of these risks present themselves
- Remarks on the importance of reporting on adverse reactions

Patients will be given a card that they should always carry with them with information about the key signs and symptoms of meningococcal infections and severe allergic reactions, and instructions to seek emergency medical care if they experience symptoms of meningococcal infections and/or severe allergic reactions.

The patient card also includes a warning message for healthcare professionals treating the patient stating that the patient is receiving crovalimab.

The key elements of the patient card provide:

- A description of the key signs and symptoms of meningococcal infections and severe allergic reactions
- A statement that the patient card should be retained for 11 months after last dose of crovalimab
- A description of when to seek urgent medical care, should signs and symptoms of these risks present themselves
- The treating physician's contact details

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING****OUTER CARTON****1. NAME OF THE MEDICINAL PRODUCT**

Piasky 340 mg solution for injection/infusion  
crovalimab

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each vial of 2 mL contains 340 mg of crovalimab.  
Each mL of solution for injection/infusion contains 170 mg crovalimab.

**3. LIST OF EXCIPIENTS**

Histidine, aspartic acid, arginine hydrochloride, poloxamer 188, water for injections.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Solution for injection/infusion  
340 mg/2 mL  
1 vial

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Do not shake  
For intravenous use after dilution or subcutaneous use  
Read the package leaflet before use  
For single use only

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children

**7. OTHER SPECIAL WARNING(S), IF NECESSARY****8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator  
Keep the vial in the outer carton to protect from light  
See package leaflet for information on temperature excursions  
Tick one box for each day stored outside refrigeration, do not exceed 7 days  
Do not freeze

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE****11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Roche Registration GmbH  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/24/1848/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY****15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

piasky 340 mg/2 ml

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b> <b>VIAL LABEL</b>
--

<b>1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b>
--

Piasky 340 mg injection/infusion  
crovalimab  
IV use after dilution/SC use

<b>2. METHOD OF ADMINISTRATION</b>
------------------------------------

<b>3. EXPIRY DATE</b>
-----------------------

EXP

<b>4. BATCH NUMBER</b>
------------------------

Lot

<b>5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT</b>
--

340 mg/2 mL

<b>6. OTHER</b>
-----------------



## **B. PACKAGE LEAFLET**

## **Package leaflet: Information for the patient**

### **Piasky 340 mg solution for injection/infusion** crovalimab

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you start using this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

In addition to this leaflet, your doctor will give you a **‘Patient Card’** which lists the signs of meningococcal infection and sepsis:

- Carry it with you at all times during treatment, and
- For 11 months after your last dose of Piasky

#### **What is in this leaflet**

1. What Piasky is and what it is used for
2. What you need to know before you use Piasky
3. How to use Piasky
4. Possible side effects
5. How to store Piasky
6. Contents of the pack and other information
7. Instructions for Use

#### **1. What Piasky is and what it is used for**

##### **What Piasky is**

Piasky contains the active substance crovalimab. It belongs to a class of medicines called ‘monoclonal antibodies’, which are proteins that are designed to attach to a specific target in the body.

Piasky is also called a complement component 5 (C5) inhibitor.

##### **What Piasky is used for**

Piasky is used to treat a disease called paroxysmal nocturnal haemoglobinuria (PNH). It is used in adults and adolescents aged 12 years and older who weigh 40 kg or more, including patients with haemolysis (the breakdown of red blood cells) and clinical symptoms indicating high disease activity and patients whose disease is stable after treatment with a C5 inhibitor for at least the past 6 months.

PNH can cause the immune system to attack the body’s red blood cells, causing haemolysis that can lead to:

- Symptoms of anaemia (low levels of red blood cells), such as feeling tired or having low energy and dark urine
- Belly pain
- Difficulty swallowing

- Difficulty getting or keeping an erection (erectile dysfunction)
- The kidneys not working properly
- Blood clots, with symptoms such as progressive swelling in one leg or breathlessness when not performing strenuous activities

Patients with PNH can require regular blood transfusions.

### **How Piasky works**

The active substance in Piasky, crovalimab, attaches to the complement 5 (C5) protein, which is a part of the body's defence system called the 'complement system'. By doing so, it blocks activation of C5, which prevents the immune system from attacking and damaging red blood cells, thereby reducing the breakdown of red blood cells. This helps to reduce the symptoms of PNH and the number of blood transfusions required.

## **2. What you need to know before you use Piasky**

### **Do not use Piasky**

- if you are allergic to crovalimab or any of the other ingredients of this medicine (listed in section 6)
- if you have a meningococcal infection (a serious infection caused by *Neisseria meningitidis* bacteria that can affect the lining of the brain and spinal cord and spread throughout the blood)
- if you have not been vaccinated against meningococcal infection, unless you will take preventive treatment with antibiotics until 2 weeks after you have received this vaccination.

Do not use Piasky if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before using Piasky.

### **Warnings and precautions**

Talk to your doctor, pharmacist or nurse before using Piasky.

#### Serious meningococcal infections

Piasky can increase your risk of meningococcal infections caused by *Neisseria meningitidis* bacteria as it blocks part of the immune system. This includes serious infections such as septicaemia (blood poisoning) and meningitis (inflammation of the membranes that surround the brain and spinal cord).

- Tell your doctor straight away if you have any of the following, which may be signs of a meningococcal infection:
  - Fever
  - Feeling sick (nausea)
  - Vomiting
  - Headache
  - Confusion or irritability
  - Stiff neck or back
  - Muscle aches, with flu-like signs or symptoms
  - Sensitivity of the eyes to light
  - Rashes or spots on your skin

Talk to your doctor before you start Piasky to make sure that your vaccination against meningococcal infections is up to date – you need to be fully vaccinated at least 2 weeks before you start using Piasky. Even if you were vaccinated as a child, your doctor might decide that you need to be vaccinated again.

If you are not fully vaccinated but you need Piasky immediately, you should have the vaccine as soon as possible. Your doctor will prescribe you antibiotics from the time you start Piasky until 2 weeks after vaccination to reduce your risk of infection.

Vaccination may not always prevent this type of infection. Your doctor might decide that you need extra measures to prevent infection.

### **Patient card**

Your doctor will give you a '**Patient Card**' which lists the signs of meningococcal infection and sepsis:

- carry it with you at all times during treatment with Piasky, and
- for 11 months after your last dose of Piasky

### Other serious infections

Piasky may also increase your risk of other serious infections, such as infections caused by *Streptococcus pneumoniae* and *Haemophilus influenzae*.

- Tell your pharmacist or doctor if you have any of the following, which may be signs of an infection:
  - Fever
  - Cough
  - Chest pain
  - Tiredness
  - Feeling short of breath
  - Painful rash
  - Sore throat
  - Burning pain when passing urine
  - Feeling weak or generally unwell

Talk to your doctor before you start Piasky to make sure that your vaccination against infections caused by *Streptococcus pneumoniae* and *Haemophilus influenzae* are up to date – you need to be fully vaccinated at least 2 weeks before you start using Piasky. Even if you were vaccinated as a child, your doctor might decide that you need vaccination again.

If you are not fully vaccinated but you need Piasky immediately, you should have the vaccine as soon as possible. Your doctor will prescribe you antibiotics from the time you start Piasky until 2 weeks after vaccination to reduce your risk of infection.

Your doctor may recommend that you receive other vaccinations before treatment. Check with your doctor before treatment begins.

### Reaction due to switching from another C5 inhibitor

Before you take Piasky, tell your doctor if you have ever been treated with any other C5 inhibitor. This is because you can have a type of temporary reaction, known as a Type III immune complex reaction, during the first 30 days after you switch from another C5 inhibitor to Piasky. This can also happen if you stop using Piasky and switch to a different C5 inhibitor.

- Tell your doctor if you have any sign of this type of reaction, such as
  - joint pain or other problems related to the muscles, bones and tissues
  - numbness and tingling or a feeling of pins and needles, especially of the hands and feet
  - rash or other skin problems
  - fever

### Infusion and injection reactions

When Piasky is given as an intravenous infusion (drip into a vein) or subcutaneous injection (injection under the skin), you may have reactions to the infusion or injection. Tell your doctor or nurse straight away if you have any of the following, which may be signs of an infusion or injection reaction:

- Headache
- Lower back pain
- Pain at infusion site and elsewhere
- Swelling
- Bruising or bleeding
- Red skin
- Itching and rash

You may also have an allergic reaction to the infusion or injection. Tell your doctor or nurse straight away if you have any of the following signs of severe allergic reactions:

- Tight chest or wheezing
- Feeling short of breath
- Fever or chills
- Severe dizziness, or light headedness
- Swelling of the lips, tongue, face
- Skin itching, hives, or rash

If you have had an infusion or injection reaction, including an allergic reaction, you should confirm with your doctor or nurse if Piasky treatment should continue or not.

### Stopping treatment with Piasky

If you stop taking Piasky and do not switch to another treatment for PNH, tell your doctor immediately if you develop symptoms that are signs of intravascular haemolysis (breakdown of red blood cells in blood vessels) including:

- Symptoms of anaemia (low levels of red blood cells), such as feeling tired or having low energy and dark urine
- Belly pain
- Difficulty swallowing
- Difficulty getting or keeping an erection (erectile dysfunction)
- The kidneys not working properly
- Blood clots, with symptoms such as progressive swelling in one leg or breathlessness when not performing strenuous activities

### Antibody formation (immunogenicity)

Your immune system may make antibodies (proteins made by the body against an unwanted substance) against crovalimab, potentially leading to reduced response or loss of response to Piasky. If you experience any of the following symptoms, you should tell your doctor immediately

- Symptoms of anaemia (low levels of red blood cells), such as feeling tired or having low energy and dark urine
- Belly pain
- Difficulty swallowing
- Difficulty getting or keeping an erection (erectile dysfunction)
- The kidneys not working properly
- Blood clots, with symptoms such as progressive swelling in one leg or breathlessness when not performing strenuous activities

## **Children and adolescents**

Do not give Piasky to children under 12 years of age or children weighing less than 40 kg. This is because it has not yet been studied in this group.

## **Other medicines and Piasky**

Tell your doctor, pharmacist or nurse if you are using, have recently used, or might use any other medicines.

In particular, you must tell your doctor if you are currently being treated or have ever been treated with any other C5 inhibitor. This is because you can have a type of temporary reaction, known as a Type III immune complex reaction (see “Warnings and precautions”).

## **Pregnancy, breast-feeding and fertility**

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

There is no information about the use of Piasky in pregnant women and the effects on an unborn baby are not known. Your doctor will discuss with you the potential risks of using Piasky during pregnancy.

If you are breast-feeding, it is not known whether Piasky passes into human milk but given its characteristics, it is expected to pass into the milk. Your doctor will discuss with you the potential risks of using Piasky during breast-feeding.

## **Driving and using machines**

Piasky has no or little influence on the ability to drive and use machines.

## **3. How to use Piasky**

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

### **Vaccines given before you use Piasky**

At least 2 weeks before you start treatment with Piasky, your doctor will give you a vaccine against meningococcal infections if you have not had one before, or if your vaccination is outdated.

If you start treatment with Piasky less than 2 weeks after receiving this vaccination, your doctor will prescribe antibiotics for at least 2 weeks after you have been vaccinated - to reduce the risk of infection.

### **How to use Piasky**

Piasky is given as an intravenous infusion (drip into a vein) or as an injection under the skin (subcutaneous injection).

Only the first dose will be given as an intravenous infusion by a healthcare professional. The next doses are given as a subcutaneous injection. After training, you or your caregiver may do the subcutaneous injection of Piasky at home without medical supervision.

Your doctor or nurse will provide training to you or your caregiver on how to prepare this medicine and how to take or give the subcutaneous injections. Read carefully and follow the instructions provided in the ‘**Instructions for Use**’ at the end of this leaflet.

## **When to use Piasky**

Your first dose will be given on Day 1 by a healthcare professional. This is the first loading dose, which is higher than the doses given later in your treatment. Additional loading doses will be given on Days 2, 8, 15, and 22.

After this, Piasky will be given on Day 29 and then every 4 weeks as a subcutaneous injection. These are the maintenance doses.

If you were previously receiving another medicine for PNH known as a ‘complement inhibitor’, the first loading dose of Piasky should be given when you were scheduled to receive the next dose of that medicine.

## **How much Piasky to use**

Your doctor will prescribe a dose and treatment plan based on how much you weigh.

If you weigh 40 kg or more, but less than 100 kg:

- Your first loading dose on Day 1 will be 1 000 mg, given by intravenous infusion over 60 minutes
- Your next loading doses on Day 2, 8, 15 and 22 will be 340 mg, given as a single subcutaneous injection
- You will be given a maintenance dose of 680 mg, given as two subcutaneous injections, on Day 29 and then every 4 weeks thereafter.

If you weigh 100 kg or more:

- Your first loading dose on Day 1 will be 1 500 mg, given by intravenous infusion over 90 minutes
- Your next loading doses on Day 2, 8, 15 and 22 will be 340 mg, given as a single subcutaneous injection
- You will be given a maintenance dose of 1 020 mg, given as three subcutaneous injections, on Day 29 and then every 4 weeks thereafter.

Your maintenance dose may change if your body weight changes during treatment with Piasky. Talk to your doctor if your weight goes above, or falls below 100 kg. Your doctor or nurse should monitor your weight on an ongoing basis.

## **If you use more Piasky than you should**

If you think that you have used more Piasky than prescribed, please contact your doctor, pharmacist or nurse for advice.

## **If you forget to use Piasky**

For the treatment to be fully effective, it is very important to take Piasky as prescribed.

- If you miss an appointment with your doctor or nurse to get your injections, make another one straight away.
- If you or your caregiver forget to inject all or some of your dose of Piasky at home, take the missed dose or missed part of the dose as soon as possible and then take the next dose at the normal planned time. Do not double a dose to make up for a missed dose. Check with your doctor, pharmacist or nurse if you are not sure.

## If you stop using Piasky

Do not stop treatment with Piasky unless you have discussed this with your doctor first. This is because stopping treatment will stop the effect of the medicine. This may make your PNH symptoms come back or get worse.

## 4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Your doctor will discuss the possible side effects with you and explain the risks and benefits of Piasky with you before treatment.

Piasky can cause some side effects that you need to tell your doctor about straight away.

The most serious side effects are **meningococcal infection and severe allergic reaction**.

- If you have any following signs of a **meningococcal infection**, you should immediately inform your doctor:
  - Fever
  - Feeling sick (nausea or vomiting)
  - Headaches
  - Confusion or irritability
  - Stiff neck or back
  - Muscle aches with flu-like symptoms
  - Sensitivity of the eyes to light
  - Skin rashes or spots
- If you have any following signs of a **severe allergic reaction**, you should immediately inform your doctor:
  - Tight chest or wheezing
  - Feeling short of breath
  - Fever or chills
  - Severe dizziness
  - Light headedness
  - Swelling of the lips, tongue, face
  - Skin itching, hives, or rash

**Very common** (may affect more than 1 in 10 people):

- Fever
- A reaction caused by switching from another C5 inhibitor (Type III immune complex reaction; symptoms may include red skin, itching or pain)
- Nose and throat (upper respiratory tract) infection. Symptoms may include runny nose, sneezing, sore throat and cough
- Reactions to the infusion
- Headache

**Common** (may affect up to 1 in 10 people):

- Allergic reactions (hypersensitivity)
- Urinary tract infection
- Lung infection (pneumonia)
- Reaction to the injection
- Sore throat and runny nose (nasopharyngitis)
- Joint pain (arthralgia)
- Abdominal pain
- Diarrhoea



- Extreme tiredness/weakness (asthenia)
- Fatigue
- Rash
- Respiratory tract infection

**Uncommon** (may affect up to 1 in 100 people)

- Bacterial infection (bacteraemia)
- Infection of the kidneys (pyelonephritis)
- Severe reaction to an infection (sepsis), which can be accompanied by severe low blood pressure (septic shock)
- Local reaction at injection site

Tell your doctor, pharmacist or nurse if you notice any of the other side effects listed above. If you are not sure what the side effects above are, ask your doctor to explain them to you.

### **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#).<sup>\*</sup> By reporting side effects you can help provide more information on the safety of this medicine.

## **5. How to store Piasky**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C). Do not freeze.

Prior to administration, unopened vials of Piasky may be stored out of the refrigerator at room temperature if needed and then returned to refrigeration. For temperature excursions outside 2 °C – 8 °C, unopened vials in their original carton may be kept at room temperature (up to 30 °C) for a total combined time of no longer than 7 days. You can tick one box on the inside of the vial carton for each day Piasky is stored outside refrigeration. Discard if stored out of the refrigerator at room temperature for longer than 7 days.

Keep the vial in the outer carton in order to protect from light.

Do not store syringes filled with this medicine. Syringes filled with Piasky must be used right away.

Do not use this medicine if you notice it is cloudy, discoloured or contains particles.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

More details are provided in the Instructions for Use. Please read carefully before using Piasky vial.

## **6. Contents of the pack and other information**

### **What Piasky contains**

- The active substance is crovalimab. Each glass vial contains 340 mg of crovalimab in 2 mL of solution. Each mL of solution for injection/infusion contains 170 mg crovalimab.
- The other ingredients are histidine, aspartic acid, arginine hydrochloride, poloxamer 188 and water for injections.

### **What Piasky looks like and contents of the pack**

Piasky is a clear to strongly opalescent and almost colourless to brownish-yellow solution for injection/infusion (injection/infusion).

Each pack of Piasky contains 1 glass vial of 2 ml.

### **Marketing Authorisation Holder**

Roche Registration GmbH  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

### **Manufacturer**

Roche Pharma AG  
Emil-Barell-Strasse 1  
79639 Grenzach-Wyhlen  
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien,  
Luxembourg/Luxemburg**  
N.V. Roche S.A.  
België/Belgique/Belgien  
Tél/Tel: +32 (0) 2 525 82 11

**Latvija**  
Roche Latvija SIA  
Tel: +371 - 6 7039831

**България**  
Рош България ЕООД  
Тел: +359 2 474 5444

**Lietuva**  
UAB "Roche Lietuva"  
Tel: +370 5 2546799

**Česká republika**  
Roche s. r. o.  
Tel: +420 - 2 20382111

**Magyarország**  
Roche (Magyarország) Kft.  
Tel: +36 1 279 4500

**Danmark**  
Roche Pharmaceuticals A/S  
Tlf.: +45 - 36 39 99 99

**Nederland**  
Roche Nederland B.V.  
Tel: +31 (0) 348 438050

**Deutschland**  
Roche Pharma AG  
Tel: +49 (0) 7624 140

**Norge**  
Roche Norge AS  
Tlf: +47 - 22 78 90 00

**Eesti**

Roche Eesti OÜ  
Tel: + 372 - 6 177 380

**Ελλάδα, Κύπρος**

Roche (Hellas) A.E.  
Ελλάδα  
Τηλ: +30 210 61 66 100

**España**

Roche Farma S.A.  
Tel: +34 - 91 324 81 00

**France**

Roche  
Tél: +33 (0) 1 47 61 40 00

**Hrvatska**

Roche d.o.o.  
Tel: +385 1 4722 333

**Ireland, Malta**

Roche Products (Ireland) Ltd.  
Ireland/L-Irlanda  
Tel: +353 (0) 1 469 0700

**Ísland**

Roche Pharmaceuticals A/S  
c/o Icepharma hf  
Sími: +354 540 8000

**Italia**

Roche S.p.A.  
Tel: +39 - 039 2471

**Österreich**

Roche Austria GmbH  
Tel: +43 (0) 1 27739

**Polska**

Roche Polska Sp.z o.o.  
Tel: +48 - 22 345 18 88

**Portugal**

Roche Farmacêutica Química, Lda  
Tel: +351 - 21 425 70 00

**România**

Roche România S.R.L.  
Tel: +40 21 206 47 01

**Slovenija**

Roche farmacevtska družba d.o.o.  
Tel: +386 - 1 360 26 00

**Slovenská republika**

Roche Slovensko, s.r.o.  
Tel: +421 - 2 52638201

**Suomi/Finland**

Roche Oy  
Puh/Tel: +358 (0) 10 554 500

**Sverige**

Roche AB  
Tel: +46 (0) 8 726 1200

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu/en>.

---

## 7. Instructions for use

### Before you use the vial

**Read this entire Instructions for Use** before you or your caregiver start using Piasky vial and each time you get a new prescription. There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment.

Your doctor may decide that you or your caregiver can take or give the Piasky injections.

- In this case, your doctor or nurse will show you or your caregiver how to inject your dose of Piasky the right way.
- **Do not** use Piasky vial until your doctor or nurse has trained you or your caregiver on the right way to inject.
- **Do not** inject into a vein (intravenous injection).

### Storage and handling

- Store Piasky vial in its original carton in the refrigerator between 2 °C – 8 °C until ready to use.
- Once removed from the refrigerator, unopened vials in their original carton may be kept at room temperature (up to 30 °C) for a total combined time of no longer than 7 days.
- For temperature excursion outside 2 °C – 8 °C, at room temperature, you can tick one box on the inside of the vial carton for each day Piasky is stored outside refrigeration. Discard if stored out of the refrigerator at room temperature for longer than 7 days.
- Keep the Piasky vial in the outer carton in order to protect from light.
- **After you remove Piasky vial from the carton, keep Piasky away from direct sunlight.**
- Keep Piasky vials, syringes, needles out of the reach of children.
- Each Piasky vial, syringe, and needle can be used only 1 time.
- Keep hands away from the end of needle during use and disposal.
- **Do not** freeze the vial. **Do not** use the vial if it has been frozen. Safely throw away the vial in a sharps container (see step 43) and contact your doctor or pharmacist.
- **Do not** use the vial if it has been kept at room temperature, up to 30 °C, for longer than 7 days. Safely throw away the vial in a sharps container (see step 43) and contact your doctor or pharmacist.
- **Do not** store syringes filled with Piasky. A syringe filled with the medicine must be used right away.
- **Do not** shake the vial.
- **Do not** reuse the vial, the syringe or the needles for another injection.
- **Do not** share your syringe and needles with other people.

### Full dose and number of injections

Your Piasky dose may **require up to 3 injections, one after the other. You may need up to 3 Piasky vials to receive your full dose.**

- Your doctor or pharmacist will tell you or your caregiver how many injections you need and how often you need to inject the medicine.
- **If your prescribed dose of Piasky is 680 mg, do 2 separate injections one after the other.**
- **If your prescribed dose of Piasky is 1 020 mg, do 3 separate injections one after the other.**
- Always use a new Piasky vial for each injection.
- If you are not sure of the dose, ask your doctor or pharmacist.
- **Do not** split your full dose if you do not have all the Piasky vials you need. Contact your doctor or pharmacist.

### Supplies needed for 1 injection

**This list is for a single injection.** Change the number of the supplies according to the number of injections needed (see the “Full dose and number of injections” section above).


**Included in the carton:**

- 1 Piasky vial

**Not included in the carton:**

- 18 gauge with single bevel transfer needle or 21 gauge standard needle
- 25, 26 or 27 gauge injection needle with safety shield. The needle length should be from  $\frac{3}{8}$ ” (9 mm) to  $\frac{1}{2}$ ” (13 mm).
- 2-mL or 3-mL syringe
- 2 alcohol pads (1 for your skin and 1 for the vial)
- 1 sterile cotton ball or gauze
- 1 small plaster
- 1 sharps disposal or puncture-resistant container (see step 43)

**Open the carton**




- 1 Take the Piasky vial carton(s) you need out of the refrigerator. Open the carton(s) and remove the vial(s).

**Check the dose your doctor has prescribed. The full dose may require up to 3 injections one after the other.** You may need up to 3 vials to receive a full dose. Gather all the vials you need.

- 2 Place the vial(s) on a clean, flat surface.

- **Do not** use the vial if the carton is damaged, or if the perforation of the opening is broken. Safely throw away the vial in a sharps container (see step 43) and contact your doctor or pharmacist.

**Check the vial(s)**



- 3 Check the expiry date (EXP) on the vial(s).


- 4 Check the appearance of the medicine.

The medicine must be clear to strongly opalescent and almost colourless to brownish-yellow.

**5** Check the vial(s) for any damage – like cracks or scratches.

- **Do not** use if the expiry date (EXP) has passed.
  - **Do not** use if the medicine looks cloudy, discoloured, or has particles in it.
  - **Do not** use if the vial is cracked or broken.
- If you find any of above, safely throw away the vial in a sharps container (see step 43) and contact your doctor or pharmacist.

**Warm-up time**



**6** Place the vial(s) on a clean, flat surface for 30 minutes, **away from direct sunlight**. This allows the medicine to reach room temperature.

If the vial is not at room temperature, the cold medicine could make it difficult to withdraw, and harder to inject the medicine. It could also cause discomfort.

- **Do not** speed up the warming process in any way, such as microwave, warm water or direct sunlight.
- **Do not** remove the vial cap while the vial reaches room temperature.

**Collect the other supplies**




**7** Collect the other supplies, while the vial reaches room temperature.

**The list is for a single injection.** Change the number of supplies according to the number of injections you need.

Note: the colour of your supplies might differ from the illustrations.

- 1 transfer needle
- 1 injection needle with safety shield
- 1 syringe
- 2 alcohol pads – 1 for your skin and 1 for the vial
- 1 sterile cotton ball or gauze
- 1 small plaster
- 1 sharps disposal container

### Choose the injection site




**8** Piasky must only be injected in the stomach area (abdomen).

**Make sure you do not inject into the same spot multiple times in a row.** Each injection must be at least 5 cm apart from the previous one.

- **Do not** inject into the arm or thigh.
- **Do not** inject into the 5 cm area around the belly button.
- **Do not** inject into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.

### Clean the injection site



**9** Wash your hands with soap and water.

**10** Wipe the injection site with an alcohol pad and let it air dry.

- **Do not** touch, fan, or blow on the area you have cleaned.

### Clean the vial top




**11** Remove the coloured cap from the vial. Throw away the coloured cap in the sharps container (see step 43).

**12** Wipe the rubber stopper with the other alcohol pad.

- **Do not** touch the rubber stopper after it is cleaned.

### Attach the transfer needle




**13** Remove the syringe and the transfer needle from their packaging.

**14** Push and twist the transfer needle until it is fully attached onto the syringe.  
Keep the cap on the needle.

- **Do not** use the injection needle (with the safety shield) to withdraw the medicine.


### Fill the syringe with air



**15** With the needle cap still on, slowly pull back on the plunger and draw air into the syringe **to the 2-mL line**.

Note: The vial does not contain air. The air injected into the vial will allow the medicine to be withdrawn more easily and prevent the plunger from moving.

### Uncap the transfer needle




**16** Hold the syringe in the middle and carefully pull the needle cap away from the syringe.

**17** Keep the cap on the flat surface.  
You will need to put it back on the needle after transferring the medicine.

- **Do not** throw the cap away.
- **Do not** touch the needle or let the needle touch any surface after the cap has been removed.



### Inject the air into the vial



**18** Hold the vial on the flat surface and insert the needle straight down into the centre of the rubber stopper.

**19** Keep the needle in the vial and turn the vial upside down.


**20** Make sure that the tip of the needle is above the medicine.

**21** With the vial on top, push on the plunger to inject the air into the vial.

**22** Keep your fingers pressed down on the plunger to stop it from moving.

- **Do not** inject the air into the medicine, as this would make bubbles in the medicine.

### Transfer all the medicine




**23** Slide the tip of the needle down so it is within the medicine.

**24** Slowly pull back the plunger to **transfer all the medicine** into the syringe.

Make sure you **keep the tip of the needle within the medicine** at all times as the medicine is transferred into the syringe. **You may have to slide the needle down** or you may transfer some air into the syringe.

- **Do not** completely pull the needle out of the vial.
- **Do not** completely pull the plunger out of the syringe.

### Remove the air bubbles




**25** If you have any air bubbles or space filled with air in the syringe, gently tap the side of the syringe with your finger until the air bubbles rise to the top of the syringe.

**26** Slowly push the plunger up to push the air bubbles back into the vial.

If you push some medicine into the vial, slowly pull back on the plunger (more slowly this time) to transfer all the medicine from the entire vial (see steps 23 and 24).

### Recap the transfer needle



**27** Remove the syringe from the vial.


**28** Using **only one hand**, slide the needle into the cap placed on the flat surface.

**29** When the needle is covered, lift the syringe up and push the cap to fully attach over the needle.

- **Do not** hold the cap with your fingers while you slide the needle in it.

**Warning:** Do not use the transfer needle to inject the medicine. The transfer needle is too big to inject the medicine.

### Remove the transfer needle




**30** Hold the syringe, twist the transfer needle to remove it.

**31** Throw away the transfer needle into a sharps disposal container (see step 43).

- **Do not** touch the tip of the syringe after the transfer needle has been removed.

### Attach the injection needle




**32** Remove the injection needle from its packaging.

**33** Push and twist the injection needle until it is fully attached onto the syringe.

**34** Move the safety shield back toward the syringe as shown in the figure above.


### Uncap the injection needle



**35** Hold the syringe in the middle and carefully pull the needle cap away from the syringe.


- **Do not** twist or bend the cap while you are pulling it.
- **Do not** touch the needle or let it touch any surfaces after removing the needle cap.
- **Do not** put the cap back on after it has been removed because this may damage the needle.
- **Do not** use the syringe if it has been dropped or damaged.

### Adjust the plunger



**36** Slowly push the plunger to the 2 mL line.

### Insert the needle




**37** With one hand, pinch the cleaned skin area.

**38** With the other hand, hold the syringe by the middle, at an angle between 45° to 90° to the skin.

**39** With a quick motion, insert the needle all the way into the pinched skin.

- **Do not** hold or push the plunger while inserting the needle.


### Inject the medicine



**40** Slowly push the plunger all the way down to inject all the medicine.

**41** Let go of the pinched skin and remove the needle.

### Cover the injection needle



**42** After your injection, press the safety shield over the needle with the thumb **until you hear or feel a “click.”** If you do not hear a “click,” look to see that the needle is fully covered by the safety shield.

- **Do not** recap the needle with the original cap.
- **Do not** use your two hands to cover the needle.
- **Do not** remove the needle from the syringe.


### Dispose of the syringe and vial



**43** Put your used Piasky vial, syringe, needles and remaining material in a sharps disposal container right after use.

- **Do not** throw away your loose needles, syringe and vial, in your household waste.
- **Do not** try to take the syringe apart.

### Check the injection site



**44** There may be a small amount of blood or medicine at the injection site.

You can press a cotton ball or gauze until any bleeding stops. If needed, cover the injection site with a small plaster. If bleeding does not stop contact your doctor.

Your injection is now complete.

- **Do not** rub or massage the area where you have injected.

### Second or third injections

**If the prescribed dose is 2 or 3 injections one after another, start again at step 8 with another Piasky vial and new supplies.** You may need up to 3 vials for a full dose. Make sure the next injection is not at the same spot you already used.

### Disposal of syringes and vials



**Do not** throw away any medicines via wastewater or household waste.

Ask your pharmacist how to throw away medicines you no longer use. These will help protect the environment.

When the container is full, make sure you dispose of it as instructed by your doctor, nurse or pharmacist.